References
- Santarpia M, Massafra M, Gebbia V, et al. A narrative review of MET inhibitors in non-small cell lung cancer with MET exon 14 skipping mutations. Transl Lung Cancer Res. 2021;10(3):1536. doi: 10.21037/tlcr-20-1113
- Wolf J, Seto T, Han J-Y, et al. Capmatinib in MET exon 14–mutated or MET-amplified non–small-cell lung cancer. N Engl J Med. 2020;383(10):944–957. doi: 10.1056/NEJMoa2002787
- Paik PK, Felip E, Veillon R, et al. Tepotinib in non–small-cell lung cancer with MET exon 14 skipping mutations. N Engl J Med. 2020;383(10):931–943. doi: 10.1056/NEJMoa2004407
- Albers J, Friese-Hamim M, Clark A, et al. The preclinical pharmacology of tepotinib–a highly selective MET inhibitor with activity in tumors harboring MET alterations. Mol Cancer Ther. 2023;22(7):833–843. MCT-22–0537. doi: 10.1158/1535-7163.MCT-22-0537
- Terada T, Noda S, K-I I. Management of dose variability and side effects for individualized cancer pharmacotherapy with tyrosine kinase inhibitors. Pharmacol Ther. 2015;152:125–134. doi: 10.1016/j.pharmthera.2015.05.009
- Le X, Garassino M, Ahn M-J, et al. OA21. 06 ctDNA Dynamics, prognostic markers and resistance mechanisms in tepotinib-treated METex14 skipping NSCLC in the VISION Trial. J Thorac Oncol. 2023;18(11):S94–S95. doi: 10.1016/j.jtho.2023.09.107